October spotlights eye-care breakthroughs: phase 3 gene therapies, sustained delivery, and AAO trial data, plus 3 FDA clearances shaping retina, cataract, and TED care.

Veeral Sheth, MD, breaks down the LUCIA wet AMD data, plus new AAO findings on GLP-1 agents and anti-VEGF treatment burden in DME.

Isa S. K. Mohammed, MD, explains how he matches patients to PRK, LASIK, SMILE, or phakic IOLs and how prior surgery affects IOLs.

IRIS Registry data showed no change in anti-VEGF frequency, vision, or retinal thickness after patients with DME began a GLP-1RA.

Murtaza K. Adam, MD, shares pearls on haptic docking, patient selection, and preventing complications with the Yamane technique.

Uday Devgan, MD, FACS, Jordana G. Fein, MD, MS, and Carl D. Regillo, MD, FASRS, point to IOL education, emerging retina therapies, and treatment burden.

Now on the company's EYE7 smart glasses platform, Eva is designed to go beyond answering questions about the visual environment by reasoning about user needs and directly controlling the device's vision-enhancement features.

Andrew G. Lee, MD, and Drew Carey, MD, break down the visual safety of flow-diverting stents for carotid-ophthalmic aneurysms.